Tanabe’s Uplizna Defense: Obexelimab Had Already Won Phase 3
Tanabe’s Uplizna Defense: Obexelimab Had Already Won Phase 3 | Witfire Elite View Witfire Elite Competitive Strategy Case Studies Japan Pharma Long Read Pharma Market Case Studies Witfire Elite View Tanabe’s Uplizna Defense Obexelimab Had Already Won Phase 3 4SigHT is formally a long-term observational study. Strategically, its timing points to something larger: Tanabe is building a Japanese real-world evidence…
Trending News
Revolution Medicines Built a $4.3 Billion Wall Around Daraxonrasib
Revolution Medicines Daraxonrasib: The $4.3B Autopsy | Witfire Elite View Witfire Elite Oncology…
Philippines AI Liver Cancer Breakthrough: How the CANDLE Study Could Change Early Detection
Philippines AI Liver Cancer Breakthrough: How the CANDLE Study Could Change Early Detection…
Pharma Stock Market News: US-Israel-Iran War Impact on Drug Supply Chains, Oil Prices and Healthcare Stocks
The stock market is now looking at the US-Israel-Iran conflict through a sharper…
Pharma Stock Market News: US-Israel-Iran War Impact on Drug Companies, Oil Prices, and Pharma Supply Chains
The US-Israel-Iran war is affecting pharma stocks, drug supply chains, logistics costs, cold-chain…
Editorial picks
Tanabe’s Uplizna Defense: Obexelimab Had Already Won Phase 3
Tanabe’s Uplizna Defense: Obexelimab Had Already Won Phase 3 | Witfire Elite View Witfire Elite Competitive Strategy Case Studies Japan Pharma Long Read Pharma Market Case Studies Witfire Elite View Tanabe’s Uplizna Defense Obexelimab Had Already Won Phase 3 4SigHT is formally a long-term observational study. Strategically, its timing points…
Pharma Stock Market News: US-Israel-Iran War Impact on Drug Supply Chains, Oil Prices and Healthcare Stocks
Pharma Stock Market News: US-Israel-Iran War Impact on Drug Companies, Oil Prices, and Pharma Supply Chains
Moderna Flu Vaccine Reversal: FDA Refused to Review It—Then Advisers Voted 9-0 Twice
Lilly’s Germany Investment Cut: Why Pharma Capital Is Starting to Vote Against Policy Risk
Categories
Investments
business news
Entrepreneurship
Startups
June, 2026
Chokepoints & Catalysts — Vol. I, No. 1
Five intelligence-led analyses on how FDA decisions, geopolitical chokepoints, and policy shifts are repricing global pharma—covering GSK’s Nuvalent acquisition, Replimune’s RP1, India’s CRO opportunity, API dependence, and Lilly’s Germany investment cut.
Around The World
Moderna Flu Vaccine Reversal: FDA Refused to Review It—Then Advisers Voted 9-0 Twice
Moderna Flu Vaccine: From FDA Refusal to Two 9-0 Votes | Witfire Elite View Witfire Elite FDA & Regulatory Case Studies Strategy Long Read Pharma Market Case Studies Witfire Elite View Moderna Flu Vaccine Reversal FDA Refused to Review It—Then Advisers Voted 9-0 Twice Four months after FDA refused to file Moderna’s application, its vaccine advisers unanimously supported its benefit-risk…
Pharma News
Tanabe’s Uplizna Defense: Obexelimab Had Already Won Phase 3
Tanabe’s Uplizna Defense: Obexelimab Had Already Won Phase 3 | Witfire Elite View Witfire Elite Competitive Strategy Case…
Revolution Medicines Built a $4.3 Billion Wall Around Daraxonrasib
Revolution Medicines Daraxonrasib: The $4.3B Autopsy | Witfire Elite View Witfire Elite Oncology Strategy Case Studies Financing Long…
Moderna Flu Vaccine Reversal: FDA Refused to Review It—Then Advisers Voted 9-0 Twice
Moderna Flu Vaccine: From FDA Refusal to Two 9-0 Votes | Witfire Elite View Witfire Elite FDA &…